Results 241 to 250 of about 87,423 (320)

Vesicular glutamate transporter VGLUT2 expression emerges in substantia nigra dopamine neurons in mouse models of parkinsonism in the absence of neurodegeneration

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Subsets of midbrain dopamine (DA) neurons express the vesicular glutamate transporter VGLUT2 and can release the excitatory neurotransmitter glutamate. VGLUT2+ DA neurons of the substantia nigra pars compacta (SNc) were shown to be more resistant to neurodegeneration in animal models of Parkinson's disease (PD ...
Sivakumar Srinivasan   +2 more
wiley   +1 more source

Presynaptic functional trkB receptors mediate the release of excitatory neurotransmitters from primary afferent terminals in lamina II (substantia gelatinosa) of postnatal rat spinal cord

open access: green, 2008
Adalberto Merighi   +8 more
openalex   +2 more sources

The relationship between the cannabinoids and cardiac remodelling: A comprehensive review of pivotal mechanisms and emerging evidence

open access: yesBritish Journal of Pharmacology, EarlyView.
Cardiac remodelling and fibrosis after myocardial infarction or during chronic diseases, such as arterial and pulmonary hypertension or diabetes mellitus, continue to be the more important prognostic factors in determining survival, and so the search for effective anti‐fibrotic interventions is an important target for research and therapy in cardiology.
Anna Krzyżewska   +2 more
wiley   +1 more source

Central presynaptic terminals are enriched in ATP but the majority lack mitochondria. [PDF]

open access: yesPLoS One, 2015
Chavan V   +7 more
europepmc   +1 more source

Presynaptic Muscarinic Acetylcholine Receptors and TrkB Receptor Cooperate in the Elimination of Redundant Motor Nerve Terminals during Development [PDF]

open access: gold, 2017
Laura Nadal   +7 more
openalex   +1 more source

Three‐year outcomes of repeated botulinum neurotoxin A injections to the lower extremities in young children with spastic cerebral palsy in GMFCS levels I to III

open access: yesDevelopmental Medicine &Child Neurology, EarlyView.
In this study, we followed a group of children 2 to 6 years old with spastic cerebral palsy functioning in GMFCS levels I–III, over 3 years. Sixty‐five received BoNT‐A and 59 did not. Repeated BoNT‐A injections over 3 years were not associated with improvements in gross motor function or passive ankle dorsiflexion. Daily step counts, favouring the BoNT‐
Darcy Fehlings   +11 more
wiley   +1 more source

Synaptic ultrastructural alterations in human focal cortical dysplasia: Insights from volume electron microscopy

open access: yesEpilepsia, EarlyView.
Abstract Objective Focal cortical dysplasia (FCD) is a developmental malformation of the cerebral cortex and a leading cause of drug‐resistant epilepsy in children and young adults. Disruption of the excitation–inhibition (E–I) balance is a hallmark of neuronal hyperexcitability in FCD, yet the underlying synaptic ultrastructural changes remain poorly ...
Gyu Hyun Kim   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy